Press Releases

March 21, 2019

Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer’s Disease

March 19, 2019

ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson’s Disease at AD/PDTM 2019 Conference

March 15, 2019

ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results

Press Archives

In the News

February 28, 2019

Genetic Engineering and Biotechnology News – Attacking the Right Therapeutic Target in Alzheimer’s Disease

February 1, 2019

CANTECH LETTER – Could Roche’s Alzheimer’s drug failure be Promis Neurosciences gain?

December 18, 2018

DDN News – ProMIS tackles Parkinson’s and Alzheimer’s diseases

News Archives

Presentations

November 20, 2018

Narrated year to date overview Nov 2018 – video

November 6, 2018

The Critical Importance Of Selectivity When Developing Antibody Therapies For Alzheimer’s Disease And Our Current Phase 1 Design Considerations – Presentation

August 7, 2018

AAIC Report 2018 – Narrated Overview

Presentations Archives

Videos

November 20, 2018

Narrated year to date overview Nov 2018 – video

November 6, 2018

The Critical Importance Of Selectivity When Developing Antibody Therapies For Alzheimer’s Disease And Our Current Phase 1 Design Considerations – Presentation

August 7, 2018

AAIC Report 2018 – Narrated Overview

Video Archives